Asset Prioritization

Expanding Into Asia-Pacific: Life sciences opportunities and strategies for success
Objective :

Asset Prioritization Analysis to provide Strategic direction to the client in Atrial Fibrillation space along with Identification of best possible asset to support client’s future development and licensing needs.

Problem Statement:

A mid-sized pharma client was working to develop their asset portfolio and was interested in assessing best possible asset for atrial fibrillation for future development and licensing needs. The client requested evidence-based priorities in assets and products for Phase II development in atrial fibrillation, through potential licensing collaborations. Also, the client wanted to prioritise research efforts to determine the best possible asset to leverage their research portfolio.

Our Methodology:
  • Technology Assessment
  • Company Assessment
  • Commercial Assessment
  • Clinical Assessment
  • Primary Assessment
  • Matrix Analysis
  • Best Possible Asset Identified
Results:
  • Matrix Analysis positioned the top 20 companies researched.
  • The client could assess the Top companies which would effectively fit their strategic needs and objectives (the TARGET quadrant).
  • Insights into market trends for different candidates the company is developing and helping to prioritise the products.

Related Insights

CDMO Competitive Assessment in the USA and Europe
CDMO Competitive Assessment in the USA and Europe

A CDMO client based in Europe, involved DelveInsight to provide in-depth competitor assessment of companies active in the pharma CDMO area, in order to understand effective landscaping and conduct strategic decision-making for gaining competitive advantage. [...]

View Case
Product Assessment
Product Assessment

A global pharmaceutical company aimed to monitor the performances of its wide variety of newly launched oncology products based on Lead and Lag KPIs on a monthly... [...]

View Case
Market Assessment
Market Assessment

A global pharmaceutical company wished to evaluate the market value of an asset obtained by acquiring a mid-cap company. The new class of drug showed the potential in targeting multiple... [...]

View Case

Fill the form to download the case study

I consent to DelveInsight gathering details provided via this form. Check our Privacy Policy to know more.